The impacts of ercc1 gene exon viii alternative splicing on cisplatin-resistance in ovarian cancer cells

Cancer Investigation

Volumn 27, Issue 9, 2009, Pages 891-897

  Sun, Yehong ^a,b   Li, Tiyuan ^b   Ma, Kewei ^c   Tian, Zhongkai ^b   Zhu, Ying ^b   Chen, Fuqiang ^b   Hu, Gang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c JILIN UNIVERSITY   (China)

Author keywords

Alternative splicing; Cisplatin; DNA lesions repair; Drug resistance; ERCC1 exon VIII

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; DNA REPAIR; DRUG SENSITIVITY; EXON; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; NORTHERN BLOTTING; OVARY CANCER; PRIORITY JOURNAL;

ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DNA DAMAGE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; EXONS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; TRANSFECTION;

EID: 70350155230     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900902744536     Document Type: Article

References (32)

1. Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33, 9-23.
2. Siddik, Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22, 7265-7279.
3. Reed, E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998, 24, 331-344.
4. Altaha, R.; Liang, X.; Yu, J.J.; Reed, E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004, 14, 959-970.
5. Gossage, L.; Madhusudan, S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev2007, 33, 565-577.
6. Sancar, A.; Lindsey-Boltz, L.A.; Unsal-Kacmaz, K.; Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004, 73, 39-85.
7. Köberle, B.; Masters, J.R.W.; Hartley, J.A.; Wood, R.D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumors. Current Biol 1999, 9, 273-276.
8. Welsh, C.; Day, R.; McGurk, C.; Masters, J.R.W.; Wood, R.D.; Köberle, B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004, 110, 352-361.
9. McGurk, C.J.; Cummings, M.; Köberle, B.; Hartley, J.A.; Oliver, R.T.; Masters, J.R. Regulation of DNA repair gene expression in human cancer cell lines. J Cell Biochem 2006, 97, 1121-1136.
10. Ferry, K.V.; Fink, D.; Johnson, S.W.; Hamilton, T.C.; Howell, S.B. Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells. Biochem Pharmacol 1999, 57, 861-867
11. Dijt, F.J.; Fichtinger-Schepman, A.M.; Berends, F.; Reedijk, J. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 1988, 48, 6058-6062.
12. Zamble, D.B.; Lippard, S.J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995, 20, 435-439.
13. States, J.C.; Reed, E. Enhanced XPA mRNA levels in cisplatinresistant human ovarian cancer are not associated with XPA mutations or gene amplifications. Cancer Lett 1996, 108, 233-237.
14. Jordan, P.; Carmo-Fonseca, M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000, 57, 1229-1235.
15. Kartalou, M.; Essigmann, J.M. Mechanisms of resistance to cisplatin. Mutat Res 2001, 478, 23-43.
16. Rosell, R.; Taron, M.; Barnadas, A.; Scagliotti, G.; Sarries, C.; Roig, B. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003, 10, 297-305
17. Ferry, K.V.; Hamilton, T.C.; Johnson, S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000, 60, 1305-1313.
18. Shen, M.R.; Jones, I.M.; Mohrenweiser, H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998, 58, 604-608.
19. Sijbers, A.M.; de Laat, W.L.; Ariza, R.R.; Biggerstaff, M.; Wei, Y.F.; Moggs, J.G.; Carter, K.C.; Shell, B.K.; Evans, E.; de Jong, M.C.; Rademakers, S.; de Rooij, J.; Jaspers, N.G.; Hoeijmakers, J.H.; Wood, R.D. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 1996, 86, 811-822.
20. Yang, L.Y.; Li, L.; Jiang, H.; Shen, Y.; Plunkett, W. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000, 6, 773-781.
21. Parker, R.J.; Eastman, A.; Bostick-Bruton, F.; Reed, E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991, 87, 772-777.
22. Li, Q.; Gardner, K.; Zhang, L.; Tsang, B.; Bostick-Bruton, F.; Reed, E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998, 273, 23419-23425.
23. Park, J.S.; Park, S.J.; Peng, X.; Wang, M.; Yu, M.A.; Lee, S.H. Involvement of DNA-dependent protein kinase in UV-induced replication arrest. J Biol Chem 1999, 274, 32520-32527.
24. Hansen, M.B.; Nielsen, S.E.; Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989, 119, 203-210.
25. Li, Q.; Yu, J.J.; Mu, C.; Yunmbam, M.K.; Slavsky, D.; Cross, C.L.; Bostick-Bruton, F.; Reed, E. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000, 20, 645-652.
26. Selvakumaran, M.; Pisarcik, D.A.; Bao, R.; Yeung, A.T.; Hamilton, T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003, 63, 1311-1316.
27. Petit, C.; Sancar, A. Nucleotide excision repair: from E. coli to man. Biochimie 1999, 81, 15-25.
28. Wood, R.D.; Mitchell, M.; Sgouros, J.; Lindahl, T. Human DNA repair genes. Science 2001, 291, 1284-1289.
29. Youn, C.K.; Kim, M.H.; Cho, H.J.; Kim, H.B.; Chang, I.Y.; Chung, M.H.; .You, H.Z. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 2004, 64, 4849-4857.
30. Houtsmuller, A.B.; Rademakers, S.; Nigg, A.L.; Hoogstraten, D.; Hoeijmakers, J.H.; Vermeulen, W. Action of DNA repair endonuclease ERCC1/XPF in living cells. Science 1999, 284, 958-961.
31. Kiyohara, C.; Yoshimasu, K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: A metaanalysis. Int J Med Sci 2007, 4, 59-71.
32. Niedernhofer, L.J.; Essers, J.; Weeda, G.; Beverloo, B.; de Wit, J.; Muijtjens, M.; Odijk, H.; Hoeijmakers, J.H.; Kanaar, R. The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells. The EMBO J 2001, 20, 6540-6549.